PHP
NVCR icon

Parkman Healthcare Partners’s NovoCure NVCR Stock Holding History

Parkman Healthcare Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$782K – 106
2024
Q1 		$782K Buy
+50,000
New +$735K 0.1% 95

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Parkman Healthcare Partners's NVCR Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 50,000 shares — an estimated $782K sold.

Parkman Healthcare Partners first reported a position in NVCR in Q1 2024 and held it in 1 quarter. The position peaked at $782K in Q1 2024. 237 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • Parkman Healthcare Partners reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 50,000 NovoCure shares in Q2 2024, an estimated $782K.
  • Parkman Healthcare Partners first reported a position in NovoCure in Q1 2024 and held it in 1 quarter.
  • Parkman Healthcare Partners's NovoCure position peaked at $782K in Q1 2024.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.